Drug intelligence / Profile preview

adalimumab + ciprofloxacin

Development stage: Unknown
Lead developer: Abbott
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Subcutaneous, Oral

Overview

A combination therapy consisting of adalimumab (a TNF-alpha blocker) and ciprofloxacin (a fluoroquinolone antibiotic). This combination has been shown to be more effective than adalimumab monotherapy in achieving fistula closure in patients with perianal fistulizing Crohn's disease. In clinical trials, the combination demonstrated significantly higher clinical response rates (71% vs 47%) and remission rates (65% vs 33%) compared to adalimumab alone at 12 weeks. However, the beneficial effect was not maintained after discontinuation of ciprofloxacin.

Targets

TNFA (Tumor necrosis factor alpha (soluble))Topo IV (Bacterial Topoisomerase IV)DNA gyrase

Beyond the preview

Go deeper on adalimumab + ciprofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adalimumab + ciprofloxacin.

Explore the full profile